If you thought “Ozempic face” was bad, wait till you hear what it’s doing inside the body.
A massive study involving 16 million people found GLP-1 users had a 9.09 times greater risk of pancreatitis, 4.22 times greater risk of bowel obstruction, and a 3.67 times greater risk of stomach paralysis.
And if you’ve ever had pancreatitis, it is “quite a painful experience.”
What you’re hearing on the news about Ozempic is still too little, too late.
Here’s the story you’re not getting about Ozempic, the business model behind it, and why a growing number of researchers believe another pharmaceutical disaster is already unfolding in real time.
In early 2023, JP Morgan hosted its annual healthcare conference—a private, invitation-only event it describes as “the industry’s biggest gathering.”
The keynote speakers included the chairman of JPMorgan Chase, the CEO of Eli Lilly, and several managing directors of major healthcare venture capital firms.
The fourth keynote was Dr. Robert Califf.
His day job at the time: Commissioner of Food and Drugs for the United States Food and Drug Administration.
Hmm…
This wasn’t a public health symposium. It wasn’t an academic conference.
It was specifically designed for large investors, and its explicit purpose was to set the pharmaceutical industry’s financial priorities for the year ahead.
A pharmaceutical safety advocate named Kim Witczak obtained what she could from the conference’s public-facing website.
But what was being said behind closed doors?
Hellbound and Down 